Subscribe for great stories in your community!
The shareholders of the Boston biopharmaceutical company Paratek Pharmaceuticals have voted to accept a $462 million buyout, writes John George for the Philadelphia Business Journal…
Before we send you to this site, please subscribe to our daily newsletter.
